Lexeo Therapeutics (LXEO) to Release Earnings on Monday

Lexeo Therapeutics (NASDAQ:LXEO) is anticipated to release its earnings data before the market opens on Monday, March 10th. Analysts expect Lexeo Therapeutics to post earnings of ($0.81) per share for the quarter.

Lexeo Therapeutics Stock Down 3.9 %

Shares of Lexeo Therapeutics stock opened at $2.70 on Friday. The company has a quick ratio of 5.95, a current ratio of 5.95 and a debt-to-equity ratio of 0.01. Lexeo Therapeutics has a 52-week low of $2.32 and a 52-week high of $19.50. The company has a market capitalization of $89.28 million, a P/E ratio of -0.85 and a beta of 3.86. The company has a 50 day moving average of $4.98 and a 200 day moving average of $7.41.

Analysts Set New Price Targets

A number of brokerages recently commented on LXEO. HC Wainwright increased their price objective on shares of Lexeo Therapeutics from $21.00 to $23.00 and gave the company a “buy” rating in a research note on Thursday, November 14th. Chardan Capital upped their target price on shares of Lexeo Therapeutics from $23.00 to $25.00 and gave the company a “buy” rating in a report on Wednesday, November 13th. Leerink Partners reduced their target price on shares of Lexeo Therapeutics from $20.00 to $19.00 and set an “outperform” rating on the stock in a report on Wednesday, November 13th. Finally, Royal Bank of Canada restated an “outperform” rating and issued a $24.00 target price on shares of Lexeo Therapeutics in a report on Tuesday, January 21st. Five analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat, Lexeo Therapeutics currently has a consensus rating of “Buy” and an average price target of $23.80.

Lexeo Therapeutics Company Profile

Lexeo Therapeutics, Inc operates as a clinical stage genetic medicine company that focuses on hereditary and acquired diseases. The company develops LX2006, which is an AAVrh10-based gene therapy candidate for the treatment of Friedreich's ataxia (FA) cardiomyopathy; LX2020, an AAVrh10-based gene therapy candidate for the treatment of plakophilin-2 arrhythmogenic cardiomyopathy; LX2021, a gene therapy candidate for the treatment of DSP cardiomyopathy associated with it; and LX2022, a gene therapy candidate for the treatment of hypertrophic cardiomyopathy, or HCM caused by TNNI3 gene.